Výsledky vyhledávání

Akademický článek

PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.

Autor: Filik Y; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria., Bauer K; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria., Hadzijusufovic E; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria.; Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna Vienna, Austria., Haider P; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria., Greiner G; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Laboratory Medicine, Medical University of Vienna Vienna, Austria.; Ihr Labor, Medical Diagnostic Laboratories Vienna, Austria., Witzeneder N; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Laboratory Medicine, Medical University of Vienna Vienna, Austria., Hoermann G; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Laboratory Medicine, Medical University of Vienna Vienna, Austria.; MLL Munich Leukemia Laboratory Munich, Germany., Hohensinner PJ; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria., Gleixner KV; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria., Wojta J; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna Vienna, Austria.; Ludwig Boltzmann Institute for Cardiovascular Research, Medical University of Vienna Vienna, Austria., Sperr WR; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria., Valent P; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Vienna, Austria.; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2021 Dec 15; Vol. 11 (12), pp. 6042-6059. Date of Electronic Publication: 2021 Dec 15 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 ^T315I -compound mutations.

Autor: Gleixner KV; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Filik Y; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Berger D; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Schewzik C; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Schneeweiss-Gleixner M; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna Austria., Byrgazov K; Children's Cancer Research Institute (CCRI) Vienna, Austria., Sperr WR; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Mayer J; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno Czech Republic., Lion T; Children's Cancer Research Institute (CCRI) Vienna, Austria., Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2021 Sep 15; Vol. 11 (9), pp. 4470-4484. Date of Electronic Publication: 2021 Sep 15 (Print Publication: 2021).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání